Exelixis Reports Completion of Patient Enrollment in P-III CONTACT-01 Trial of Cabometyx (cabozantinib) + Tecentriq (atezolizumab) for Metastatic NSCLC
Shots:
- The company has completed the enrolment in the P-III CONTACT-01 trial evaluating cabozantinib + atezolizumab in a ratio (1:1) in 366 patients with metastatic NSCLC prior treated with an immune checkpoint inhibitor & Pt-containing CT. The study is sponsored by Roche & co-funded by Exelixis
- The 1EPs of a trial are OS & 2EPs include PFS, ORR & DoR. The study has built from cohort 7 of the P-Ib COSMIC-021 trial results
- Cabometyx has received the US FDAs approval for advanced RCC, HCC, advanced RCC, thyroid cancer & has also received regulatory approvals in the EU & other countries. Zymeworks holds the exclusive rights to develop & commercialize cabozantinib in the US
Ref: Businesswire | Image: Exelixis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
